ArticleBreast cancer research and treatment2015

A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2.

Celine M Vachon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.